pharmaphorum Top Stories - 4 November 2024
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
In this week’s top stories, there’s hope for T1D patients, as Eledon Pharmaceuticals, Inc. reveals a potential 'functional cure' seen in two patients after receiving an islet cell transplant in combination with its experimental immunosuppressant drug.
Elsewhere in the news, we went from the UK Budget and what that means for the NHS and life sciences to Teva being fined €462.6m by the European Commission for an antitrust delay to MS drug rivals.
And while 诺华 invested substantially in the molecular glue degrader space with its partnership with Monte Rosa Therapeutics , 诺和诺德 intends to file trending GLP-1 receptor agonist drug semaglutide for MASH in 2025.
Top Stories
Eledon Pharmaceuticals has revealed that two patients with type 1 diabetes achieved a 'functional cure' after receiving a transplant of insulin-producing islet cells in combination with its experimental immunosuppressant drug.
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and European regulatory filings in the first half of next year.
In a historic moment today, Rachel Reeves became the first female UK Chancellor to deliver a Budget statement, which featured a major cash injection into the NHS.
领英推荐
The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.
Register to join our upcoming webinars:
Enabling site success: Key insights to reducing burden and increasing access Sponsored by Syneos Health - Nov 12 2024, 10am ET / 4pm CET / 3pm GMT.
The AI effect in pharma commercial strategy: From data to real-time insight & actions Sponsored by Trueblue - Dec 4 2024, 2pm GMT - 3pm CET - 9am EST
In a recent pharmaphorum webinar sponsored by EVERSANA INTOUCH , editor-in-chief Jonah Comstock sat down with Melanie Walsh , Senior Director, IBD Franchise Customer Experience and Digital Innovation, at Takeda , to learn some tips for successful content transformation. How can organisations successfully ride the wave of this transformation, find the right content strategy for them, and avoid getting left behind? More in the article here.